• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 6
  3. Author

Online ISSN: 2515-8260

Volume7, Issue6

Assessment of Levetiracetam for the Treatment of Epilepsy

    Ms. Samera Ali Siddique

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 6, Pages 889-896

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Epilepsy is a disease related to central nervous system disorder where brain activity become unusual, thereby a patient experience a seizures or periods of strange behaviour, vibrations, and sometimes loss of consciousness. It might be due to genetic disorder or some sort of brain injury, such as shock or stroke. It requires a long duration treatment of drug therapy for getting cured. As per various researches half of patients do not pass the initial antiepileptic treatment and around 35 per cent are highly resistant to medical treatment, demonstrating the rising requirement for more effectual and improved tolerated medicines. Levetiracetam is an adjunctive management of seizures in victims with epilepsy, the fourth most general neurological chaos distressing individuals of different age groups. Its pharmacokinetic compensation comprise fast and approximately full absorption, limited irrelevant binding with plasma protein, no activation of enzymes, no connections with other products, and unfair metabolism external the liver.Yet another advantage is the provision of an intravenous injection. This has been shown to be efficient as adjunctive treatment for partial-onset refractory seizures, primary widespread tonic-conic seizures, and juvenile myoclonic seizure. In addition, controlled release of carbamazepine was found to be similar to first-line treatment for partial-onset seizure, together in effectiveness and acceptability.
Keywords:
    Adjunctive therapy Antiepileptic drug therapy Carbamazepine Central nervous system Epilepsy Intravenous injection Levetiracetam
  • PDF (218 K)
  • XML
(2020). Assessment of Levetiracetam for the Treatment of Epilepsy. European Journal of Molecular & Clinical Medicine, 7(6), 889-896.
Ms. Samera Ali Siddique. "Assessment of Levetiracetam for the Treatment of Epilepsy". European Journal of Molecular & Clinical Medicine, 7, 6, 2020, 889-896.
(2020). 'Assessment of Levetiracetam for the Treatment of Epilepsy', European Journal of Molecular & Clinical Medicine, 7(6), pp. 889-896.
Assessment of Levetiracetam for the Treatment of Epilepsy. European Journal of Molecular & Clinical Medicine, 2020; 7(6): 889-896.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 174
  • PDF Download: 245
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus